{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:33Z","timestamp":1788401613202,"version":"build-2803163510"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In a previous study, we found a possible connection between pre-vaccination CD3+CD56+ T cells and seroresponse to influenza vaccination in immunosuppressed patients. Decreased circulating CD3+CD56+ T cells have been described in severe COVID-19, but their role in vaccination is unknown. This study evaluated the humoral immune response after SARS-CoV-2 vaccination in children with cancer following two doses of the BNT162b2 mRNA vaccine. We investigated the relationship between cellular immunity (including CD3+CD56+ T cells) and the post-vaccination antibody response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, prospective cohort study was completed by recruiting patients receiving chemotherapy and healthy controls, who received two doses of the BNT162b2 mRNA vaccine. Flow cytometric analysis of peripheral blood lymphocyte subpopulations was performed before vaccination; serum anti-SARS-CoV-2 IgG was measured before vaccination and 21\u201328 days after the second vaccination. We evaluated the relationship between various cellular parameters before vaccination and antibody response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serological response was assessed in 20 oncology patients and 13 healthy controls. The seroconversion rate was 55% among oncology patients and 92.3% among healthy controls (p = 0.023). Geometric mean fold increase (GMFI) of the titers was 6.69 and 41.64 (p = 0.011), respectively. Flow cytometric analysis revealed a significantly higher seroconversion rate in patients with higher baseline CD3+CD56+ T cell (p = 0.044) and CD56+ NK (p = 0.038) cell counts. Based on GMFI, we found a positive association between a greater antibody response and higher baseline CD4+ (p = 0.007), CD4+CD3+CD56+ (p = 0.019), and CD4+ MAIT (p = 0.010) cell counts, as well as a higher CD4\/CD8 ratio (p = 0.029).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study suggests that an adequate humoral immune response can be induced by the SARS-CoV-2 mRNA vaccine in pediatric oncology patients. We explored for the first time the possible association between pre-vaccination T lymphocyte subpopulations (CD3+CD56+, CD56+ NK, CD4+, CD4+CD3+CD56+ cells) and the antibody response to the COVID-19 vaccine. We have similar observations as previously reported with influenza vaccination, suggesting that CD3+CD56+ T cells may be involved in the immune response to SARS-CoV-2 vaccines. We highlight the connection between pre-vaccination CD4+ MAIT cell populations and the antibody response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1728845","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:44:35Z","timestamp":1770273875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Csaba","family":"P\u00e9terfia","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt I.","family":"Koml\u00f3si","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell- and Immunobiology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"P\u00f3s","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell- and Immunobiology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolett","family":"Lupsa","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell- and Immunobiology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra","family":"Fekete","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cell- and Immunobiology, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"B\u00f6r\u00f6cz","sequence":"additional","affiliation":[{"name":"Department of Immunology and Biotechnology, Medical School, University of P\u00e9cs","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timea","family":"Dergez","sequence":"additional","affiliation":[{"name":"Institute of Bioanalysis, Medical School, University of Pecs","place":["Pecs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin A.","family":"Leibinger","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Benedek","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Vojcek","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Vertike","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Csan\u00e1di","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Unit, Heim Pal Children\u2019s Hospital","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hauser","sequence":"additional","affiliation":[{"name":"Haematology\/Oncology and Pediatric Bone Marrow Transplantation Unit, Child Health Centre, Borsod-Abauj-Zemplen County Hospital","place":["Miskolc, Hungary"]},{"name":"Faculty of Health Sciences, University of Miskolc","place":["Miskolc, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla Gy\u00f6rgyi","family":"Tiszlavicz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Szeged","place":["Szeged, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel J\u00e1nos","family":"Erd\u00e9lyi","sequence":"additional","affiliation":[{"name":"Pediatric Centre, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit \u00c1gota","family":"Br\u00fcckner","sequence":"additional","affiliation":[{"name":"Pediatric Centre, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Pediatric Centre, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolett Jusztina","family":"Beniczky","sequence":"additional","affiliation":[{"name":"Pediatric Centre, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timea","family":"Berki","sequence":"additional","affiliation":[{"name":"Department of Immunology and Biotechnology, Medical School, University of P\u00e9cs","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Ott\u00f3ffy","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of P\u00e9cs Medical School","place":["P\u00e9cs, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","unstructured":"Coronavirus disease (COVID-19) Epidemiological Updates and Monthly Operational Updates"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.668484","article-title":"Coronavirus disease 2019 in children","volume":"9","author":"Borrelli","year":"2021","journal-title":"Front Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11912-022-01207-1","article-title":"COVID-19 in children with cancer","volume":"24","author":"Kahn","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e29005","DOI":"10.1002\/pbc.29005","article-title":"Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review","volume":"68","author":"Meena","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2119763","article-title":"Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis","volume":"18","author":"Yin","year":"2022","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-022-01233-3","article-title":"Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis","volume":"15","author":"Sakuraba","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.002","article-title":"The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience","volume":"154","author":"Revon-Riviere","year":"2021","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac570","article-title":"Longitudinal immune response to 3 doses of messenger RNA vaccine against coronavirus disease 2019 (COVID-19) in pediatric patients receiving chemotherapy for cancer","volume":"76","author":"Lehrnbecher","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2022.23.6.2049","article-title":"Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases","volume":"23","author":"Poparn","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00585-12","article-title":"Absolute lymphocyte count predicts the response to new influenza virus H1N1 vaccination in pediatric cancer patients","volume":"20","author":"Mavinkurve-Groothuis","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012118","article-title":"Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients","volume":"8","author":"Amarin","year":"2024","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26110","article-title":"Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer","volume":"63","author":"Choi","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24893","article-title":"Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy","volume":"61","author":"Ott\u00f3ffy","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690940","article-title":"Baseline CD3+CD56+ (NKT-like) cells and the outcome of influenza vaccination in children undergoing chemotherapy","volume":"12","author":"Leibinger","year":"2021","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1470734","article-title":"Immune response to influenza vaccination in children with cancer","volume":"14","author":"Doganis","year":"2018","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e20200872","DOI":"10.1084\/jem.20200872","article-title":"Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients","volume":"217","author":"Jouan","year":"2020","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"eabe1670","DOI":"10.1126\/sciimmunol.abe1670","article-title":"MAIT cell activation and dynamics associated with COVID-19 disease severity","volume":"5","author":"Parrot","year":"2020","journal-title":"Sci Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00870-z","article-title":"Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity","volume":"22","author":"Flament","year":"2021","journal-title":"Nat Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10020-022-00484-7","article-title":"MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine","volume":"28","author":"Boulouis","year":"2022","journal-title":"Mol Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.immuni.2021.05.002","article-title":"Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia","volume":"54","author":"Kreutmair","year":"2021","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108630","article-title":"Major reduction of NKT cells in patients with severe COVID-19 pneumonia","volume":"222","author":"Zingaropoli","year":"2021","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24109047","article-title":"Alterations in the CD56\u2013 and CD56+ T cell subsets during COVID-19","volume":"24","author":"Vavilova","year":"2023","journal-title":"IJMS"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e29443","DOI":"10.1002\/pbc.29443","article-title":"SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors","volume":"69","author":"Wimberly","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.puhe.2022.09.001","article-title":"COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis","volume":"212","author":"Prabani","year":"2022","journal-title":"Public Health"},{"key":"B28","unstructured":"Comirnaty COVID-19 mRNA vaccine"},{"key":"B29","unstructured":"EUROIMMUN US inc. Anti-SARS-coV-2 ELISA (IgG) - IFU"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01052.x","article-title":"Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis","volume":"80","author":"Huenecke","year":"2008","journal-title":"Eur J Haematology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70200-2","article-title":"Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulations","volume":"130","author":"Comans-Bitter","year":"1997","journal-title":"J Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPH.0000000000000697","article-title":"Immune dysfunction after completion of childhood leukemia therapy","volume":"39","author":"Perkins","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/707691","article-title":"Guidelines on vaccinations in paediatric haematology and oncology patients","volume":"2014","author":"Cesaro","year":"2014","journal-title":"BioMed Res Int"},{"key":"B34","unstructured":"Vaccines for moderately to severely immunocompromised people"},{"key":"B35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic Malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.09.013","article-title":"Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease","volume":"29","author":"Shoji","year":"2023","journal-title":"J Infection Chemotherapy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11050989","article-title":"BNT162b2 COVID-19 vaccines in children, adolescents and young adults with cancer\u2014A 1-year follow-up","volume":"11","author":"Donze","year":"2023","journal-title":"Vaccines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00520-024-08422-5","article-title":"Pediatric cancer patients vaccinated against SARS-CoV-2\u2014a clinical and laboratory follow-up","volume":"32","author":"Siebald","year":"2024","journal-title":"Support Care Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35096","article-title":"COVID-19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T-cells","volume":"155","author":"Parker","year":"2024","journal-title":"Intl J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092562","article-title":"Immune Response following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer Patients","volume":"15","author":"Schmidt","year":"2023","journal-title":"Cancers"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e30785","DOI":"10.1002\/pbc.30785","article-title":"SARS-CoV-2 vaccination response in pediatric oncology patients","volume":"71","author":"D\u2019Souza","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110755","article-title":"Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34503","article-title":"Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study","volume":"10","author":"Mastronuzzi","year":"2024","journal-title":"Heliyon"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13202","article-title":"Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy","volume":"23","author":"Jedicke","year":"2022","journal-title":"HIV Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11111664","article-title":"SARS-coV-2 mRNA vaccine response in people living with HIV according to CD4 count and CD4\/CD8 ratio","volume":"11","author":"Vergori","year":"2023","journal-title":"Vaccines"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2021.06.005","article-title":"Natural killer cells and unconventional T cells in COVID-19","volume":"49","author":"Bj\u00f6rkstr\u00f6m","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1615\/critrevimmunol.2014010604","article-title":"NK cells and their ability to modulate T cells during virus infections","volume":"34","author":"Cook","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.07.004","article-title":"Boosting vaccine efficacy the natural (killer) way","volume":"36","author":"Rydyznski","year":"2015","journal-title":"Trends Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1010","DOI":"10.1002\/cti2.1010","article-title":"Vaccinating for natural killer cell effector functions","volume":"7","author":"Wagstaffe","year":"2018","journal-title":"Clin Transl Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-022-00443-2","article-title":"NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals","volume":"28","author":"Cuapio","year":"2022","journal-title":"Mol Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cell.2017.11.036","article-title":"Initiation of antiviral B cell immunity relies on innate signals from spatially positioned NKT cells","volume":"172","author":"Gaya","year":"2018","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.immuni.2018.02.008","article-title":"NKTeeing up B cell responses to viral infection","volume":"48","author":"Fontana","year":"2018","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032743","article-title":"Natural killer T-like cells: immunobiology and role in disease","volume":"24","author":"Almeida","year":"2023","journal-title":"IJMS"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.06.001","article-title":"Human CD3+CD56+NKT-like cells express a range of complement receptors and C3 activation has negative effects on these cell activity and effector function","volume":"82","author":"Min","year":"2021","journal-title":"Hum Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102885","article-title":"Reappearance of effector T cells is associated with recovery from COVID-19","volume":"57","author":"Odak","year":"2020","journal-title":"EBioMedicine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108708","article-title":"Can we define CD3+CD56+ cells as NKT cells with impunity","volume":"226","author":"Lenart","year":"2021","journal-title":"Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02653-9","article-title":"The role of unconventional T cells in COVID-19","volume":"191","author":"Orumaa","year":"2022","journal-title":"Ir J Med Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.01.005","article-title":"Are NKT cells a useful predictor of COVID-19 severity","volume":"55","author":"Koay","year":"2022","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048941","article-title":"Deep phenotypical characterization of human CD3+CD56+ T cells by mass cytometry","volume":"51","author":"Romero-Olmedo","year":"2021","journal-title":"Eur J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300147","article-title":"The emerging role of MAIT cell responses in viral infections","volume":"211","author":"Sandberg","year":"2023","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.1c00359","article-title":"Chemical modulators of mucosal associated invariant T cells","volume":"54","author":"Mak","year":"2021","journal-title":"Acc Chem Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1615\/CritRevImmunol.2021040877","article-title":"MAIT cells in respiratory viral infections in mouse and human","volume":"41","author":"Long","year":"2021","journal-title":"Crit Rev Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11653","article-title":"MAIT cells are activated during human viral infections","volume":"7","author":"Van Wilgenburg","year":"2016","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax8819","article-title":"MAIT cell activation augments adenovirus vector vaccine immunogenicity","volume":"371","author":"Provine","year":"2021","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v7i1.525","article-title":"Use of a MAIT activating ligand, 5-OP-RU, as a mucosal adjuvant in a murine model of vibrio cholerae O1 vaccination","volume":"7","author":"Jensen","year":"2022","journal-title":"PAI"},{"key":"B70","doi-asserted-by":"publisher","first-page":"10060","DOI":"10.1038\/s41598-020-66964-0","article-title":"Mucosal-associated invariant T (MAIT) cells provide B-cell help in vaccinated and subsequently SIV-infected Rhesus Macaques","volume":"10","author":"Rahman","year":"2020","journal-title":"Sci Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112310","article-title":"MAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity","volume":"42","author":"Pankhurst","year":"2023","journal-title":"Cell Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e1011485","DOI":"10.1371\/journal.ppat.1011485","article-title":"Targeting the MR1-MAIT cell axis improves vaccine efficacy and affords protection against viral pathogens","volume":"19","author":"Rashu","year":"2023","journal-title":"PloS Pathog"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2024.101412","article-title":"Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity","volume":"67","author":"Amini","year":"2024","journal-title":"Curr Opin Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975980","article-title":"Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients","volume":"12","author":"Benitez Fuentes","year":"2022","journal-title":"Front Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.12688\/f1000research.110268.2","article-title":"Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain","volume":"11","author":"Benitez Fuentes","year":"2022","journal-title":"F1000Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1728845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:44:37Z","timestamp":1770273877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1728845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2026.1728845"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1728845","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1728845"}}